Cascade filtration (CF) with the Haemonetics MCS+: a new technical adaptation

Area of Science:

• Nephrology
• Hematology
• Cardiovascular Medicine

Background:

• Continuous flow (CF) apheresis, established in 1980, has primarily utilized two-vein procedures.
• Existing two-vein CF methods present limitations hindering broader application.
• Advancements in apheresis technology are crucial for expanding treatment options.

Purpose of the Study:

• To report the initial clinical application of a novel single-needle continuous flow (CF) apheresis technique.
• To evaluate the safety and efficacy of single-needle CF apheresis in diverse patient populations.
• To identify potential limitations of the single-needle CF apheresis procedure.

Main Methods:

• The study employed the Haemonetics MCS+ apparatus for single-needle CF apheresis.
• Twenty apheresis procedures were performed across multiple patient sessions (1-4 per patient).
• Patient conditions included TTP, post-hepatitic cryoglobulinemia, familial hypercholesterolemia, and Guillan-Barrè Syndrome.

Main Results:

• The single-needle CF apheresis was successfully implemented without any adverse events.
• Achieved expected laboratory and clinical outcomes for all treated patients.
• Procedure duration averaged 231 +/- 48 minutes, approximately 40% longer than two-needle methods.

Conclusions:

• Single-needle CF apheresis represents a safe and effective alternative to traditional two-vein procedures.
• This technique shows promise for managing various hematological and autoimmune conditions.
• Extended procedure time is a notable limitation requiring further optimization.